Lenvima (lenvatinib) / Eisai, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 53 Diseases   490 Trials   490 Trials   8927 News 


«12...3940414243444546474849...123124»
  • ||||||||||  Imfinzi (durvalumab) / AstraZeneca, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial initiation date, Trial primary completion date:  Durvalumab Plus Lenvatinib as First-line Treatment for Unresectable Hepatocellular Carcinoma (clinicaltrials.gov) -  Jan 26, 2023   
    P2,  N=25, Not yet recruiting, 
    Trial primary completion date: Jun 2024 --> Dec 2023 Initiation date: Apr 2022 --> Apr 2023 | Trial primary completion date: Mar 2023 --> Mar 2024
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Retrospective data, Journal, Metastases:  Lenvatinib Versus Sorafenib in Advanced Hepatic Cell Carcinoma: A Double Center Retrospective Analysis. (Pubmed Central) -  Jan 26, 2023   
    The 3-month AFP ratio of 1.36 may be a potentially useful cutoff for considering a switch to other treatments in patients radiologically diagnosed with stable or progressive disease. Lenvatinib was found to be better than Sorafenib in terms of both survival and toxicity, in advanced hepatic cell carcinoma patients.
  • ||||||||||  Tevimbra (tislelizumab-jsgr) / BeiGene, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enrollment open, Trial initiation date:  FRONT-1: HAIC Sequential TAE Combined With Lenvatinib and Tislelizumab in Unresectable HCC (clinicaltrials.gov) -  Jan 23, 2023   
    P2,  N=65, Recruiting, 
    Currently, HAIC combined with targeted therapy or immunotherapy has attracted significant attention. Not yet recruiting --> Recruiting | Initiation date: Oct 2022 --> Feb 2022
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal, PD(L)-1 Biomarker, IO biomarker:  Patient-Derived Primary Cancer-Associated Fibroblasts Mediate Resistance to Anti-Angiogenic Drug in Ovarian Cancers. (Pubmed Central) -  Jan 22, 2023   
    Ascertaining direct experimental proof of the role of CAFs in developing resistance to specific anti-angiogenic drugs will provide an opportunity to investigate new drugs for counteracting CAF resistance and "normalizing/re-educating" TME in aggressive ovarian cancers. Our data provide a unique experimental tool for the personalized testing of anti-angiogenic drugs, positively predicting the development of future resistance to anti-angiogenic drugs well before it is clinically encountered in patients.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal:  A Supramolecular Nanoassembly of Lenvatinib and a Green Light-Activatable NO Releaser for Combined Chemo-Phototherapy. (Pubmed Central) -  Jan 22, 2023   
    The supramolecular complex is stable in a culture medium, and its biological activity has been evaluated against HEP-G2 hepatocarcinoma cell lines in the dark and under irradiation with visible green light, using LVB at a concentration well below the IC. Comparative experiments performed using the polymeric host encapsulating the individual LVB and RD-NO components under the same experimental conditions show that the moderate cell mortality induced by the ternary complex in the dark increases significantly upon irradiation with visible green light, more likely as the result of synergism between the NO photogenerated and the chemotherapeutic.
  • ||||||||||  Journal:  Mechanisms of drug resistance in HCC. (Pubmed Central) -  Jan 22, 2023   
    Regorafenib, cabozantinib, and ramucirumab were shown to prolong survival as second-line agents...It also discusses alterations in signaling pathways, dysregulation of apoptosis, modulations in the tumor microenvironment, involvement of cancer stem cells, changes in drug metabolism/transport, tumor hypoxia, DNA repair, and the role of microRNAs in drug resistance. Understanding the interplay among these factors will provide guidance on the development of new therapeutic strategies capable of improving patient outcomes.
  • ||||||||||  Stivarga (regorafenib) / Bayer, Lenvima (lenvatinib) / Eisai, Merck (MSD), Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Review, Journal, Tumor mutational burden, PD(L)-1 Biomarker, IO biomarker:  Immunotherapy in hepatocellular carcinoma: how will it reshape treatment sequencing? (Pubmed Central) -  Jan 17, 2023   
    After ICIs, offering multikinase inhibitors is a widespread approach, either shifting forward sorafenib or lenvatinib, or choosing among regorafenib or cabozantinib, already approved in the refractory setting...Despite the tissue remaining a preferred source, biomarkers discovery could take advantage of liquid biopsy to overcome the matter of tissue availability and track tumor changes. Lastly, tumor genetic phenotypes, tumor microenvironment features, gut microbiome, and markers of immune response and systemic inflammation are all potential emergent predictors of response to ICIs, pending validation in the clinical setting.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enrollment open:  PEMMELA: Pembrolizumab Plus Lenvatinib In Second Line and Third Line Malignant Pleural mesotheLioma Patients (clinicaltrials.gov) -  Jan 17, 2023   
    P2,  N=58, Recruiting, 
    Lastly, tumor genetic phenotypes, tumor microenvironment features, gut microbiome, and markers of immune response and systemic inflammation are all potential emergent predictors of response to ICIs, pending validation in the clinical setting. Active, not recruiting --> Recruiting
  • ||||||||||  Inlyta (axitinib) / Pfizer, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Review, Journal, IO biomarker:  Systemic and Targeted Therapies in Adenoid Cystic Carcinoma. (Pubmed Central) -  Jan 14, 2023   
    Immunotherapy is an available option, but has been associated with only modest benefit in ACC. We go on to review other therapies that have been studied and nominate those with promise based on early clinical data.
  • ||||||||||  Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
    Journal:  A ruptured sarcomatoid hepatocellular carcinoma treated with combined immunotherapy. (Pubmed Central) -  Jan 11, 2023   
    Findings in this patient showed that combined immunotherapy was effective for sHCC. Further investigation in additional patients is required to maximize prognosis in patients with sHCC.